Skip to main content
. 2016 Jun 29;10:174–184. doi: 10.1016/j.ebiom.2016.06.040

Table 1.

Characteristics of SR10171 and rosiglitazone.

Compound IC50 (nM)a PPARγ EC50 (nM) PPARγ GAL-4 EC50 (nM) PPARγ PPRE % inhibition S273pPPARγ (20 μM) IC50 (μM)a PPARα EC50 (μM) PPARα GAL-4
Rosiglitazone 18 7.4 (100%) 10 100 No binding No activity
SR10171 220 7260 (4%) Inverse agonist 54 1.1 1.5
a

LanthaScreen; IC50 — half maximal inhibitory concentration; EC50 — half maximal effective concentration.